April 3 (Reuters) - Sierra Oncology Inc SRRA.O :
* Sierra Oncology Inc - Sierra Oncology collaborator ICR reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr
* Sierra Oncology Inc - data supports genetically-driven clinical development strategy Sierra intends to pursue for sra737
* Sierra Oncology Inc - "gemcitabine is known to impair b-family DNA polymerases, further supporting rationale for its clinical combination with sra737." Source text for Eikon: ID:nCNWT1Dpca Further company coverage: SRRA.O